Keeping Pace in Women's Cancer: The Role of PARP Inhibitors in Ovarian Cancer - a podcast by ReachMD

CME credits: 0.25

Valid until: 29-06-2021

Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-womens-cancer-role-parp-inhibitors-ovarian-cancer/11674/

The approval of PARP inhibitors for maintaining response to chemotherapy and in recurrent disease has improved outcomes for patients. Additionally, ongoing and conclusive studies are paving the way for PARP inhibitor use earlier in therapy.

This activity will discuss recent clinical trials and look at the paradigm shift with PARP inhibitors, specifically within the frontline setting. Also included is a look at how the approved and emerging PARP inhibitors can be used as monotherapy and in combination approaches.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD